Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)
Prescription GLP-1 treatments are supported by large clinical trials , which is how their effectiveness and side effects are understood
Governments across countries like China, India, Japan, and South Korea are implementing awareness campaigns and supporting healthcare reforms to tackle obesity, creating a conducive environment for market expansion
From your meal photo Log smaller meals quickly Take a photo of any meal, however small, and SNAQ's AI estimates carbs, protein, fat, fiber, and calories in seconds
Next, in vitro experiments in primary hepatocytes from DIO mice were performed to unravel possible cell autonomous effects of G49
